Our findings support the notion that CD44 isoform 4 is an anti‐metastasis therapeutic target and give valuable insight into isoform specificity in CRC that is essential for unique cancer cell states and, thus, cancer phenotypes. This evidence concerns the gene CD44 and cancer.